Cargando…

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK sam...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Man (Melody), Usmani, Saad Z., Mateos, Maria‐Victoria, Nahi, Hareth, Chari, Ajai, San‐Miguel, Jesus, Touzeau, Cyrille, Suzuki, Kenshi, Kaiser, Martin, Carson, Robin, Heuck, Christoph, Qi, Ming, Zhou, Honghui, Sun, Yu‐Nien, Parasrampuria, Dolly A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048619/
https://www.ncbi.nlm.nih.gov/pubmed/33145788
http://dx.doi.org/10.1002/jcph.1771
_version_ 1783679262117593088
author Luo, Man (Melody)
Usmani, Saad Z.
Mateos, Maria‐Victoria
Nahi, Hareth
Chari, Ajai
San‐Miguel, Jesus
Touzeau, Cyrille
Suzuki, Kenshi
Kaiser, Martin
Carson, Robin
Heuck, Christoph
Qi, Ming
Zhou, Honghui
Sun, Yu‐Nien
Parasrampuria, Dolly A.
author_facet Luo, Man (Melody)
Usmani, Saad Z.
Mateos, Maria‐Victoria
Nahi, Hareth
Chari, Ajai
San‐Miguel, Jesus
Touzeau, Cyrille
Suzuki, Kenshi
Kaiser, Martin
Carson, Robin
Heuck, Christoph
Qi, Ming
Zhou, Honghui
Sun, Yu‐Nien
Parasrampuria, Dolly A.
author_sort Luo, Man (Melody)
collection PubMed
description We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK samples from 742 patients (DARA 1800 mg subcutaneously, n = 487 [monotherapy, n = 288; combination therapy, n = 199]; DARA 16 mg/kg intravenously, n = 255 [all monotherapy, in COLUMBA]; age, 33‐92 years; weight, 28.6‐147.6 kg). Subcutaneous and intravenous DARA monotherapies were administered once every week for cycles 1‐2, once every 2 weeks for cycles 3‐6, and once every 4 weeks thereafter (1 cycle is 28 days). The subcutaneous DARA combination therapy was administered with the adaptation of corresponding standard‐of‐care regimens. PK samples were collected between cycle 1 and cycle 12. Among monotherapy studies, throughout the treatment period, subcutaneous DARA provided similar/slightly higher trough concentrations (C(trough)) versus intravenous DARA, with lower maximum concentrations and smaller peak‐to‐trough fluctuations. The PK profile was consistent between subcutaneous DARA monotherapy and combination therapies. The exposure‐response relationship between daratumumab PK and efficacy or safety end points was similar for subcutaneous and intravenous DARA. Although the ≤65‐kg subgroup reported a higher incidence of neutropenia, no relationship was found between the incidence of neutropenia and exposure, which was attributed, in part, to the preexisting imbalance in neutropenia between subcutaneous DARA (45.5%) and intravenous DARA (19%) in patients ≤50 kg. A flat relationship was observed between body weight and any grade and at least grade 3 infections. The results support the DARA 1800‐mg subcutaneous flat dose as an alternative to the approved intravenous DARA 16 mg/kg.
format Online
Article
Text
id pubmed-8048619
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80486192021-04-19 Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients Luo, Man (Melody) Usmani, Saad Z. Mateos, Maria‐Victoria Nahi, Hareth Chari, Ajai San‐Miguel, Jesus Touzeau, Cyrille Suzuki, Kenshi Kaiser, Martin Carson, Robin Heuck, Christoph Qi, Ming Zhou, Honghui Sun, Yu‐Nien Parasrampuria, Dolly A. J Clin Pharmacol Exposure Response We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK samples from 742 patients (DARA 1800 mg subcutaneously, n = 487 [monotherapy, n = 288; combination therapy, n = 199]; DARA 16 mg/kg intravenously, n = 255 [all monotherapy, in COLUMBA]; age, 33‐92 years; weight, 28.6‐147.6 kg). Subcutaneous and intravenous DARA monotherapies were administered once every week for cycles 1‐2, once every 2 weeks for cycles 3‐6, and once every 4 weeks thereafter (1 cycle is 28 days). The subcutaneous DARA combination therapy was administered with the adaptation of corresponding standard‐of‐care regimens. PK samples were collected between cycle 1 and cycle 12. Among monotherapy studies, throughout the treatment period, subcutaneous DARA provided similar/slightly higher trough concentrations (C(trough)) versus intravenous DARA, with lower maximum concentrations and smaller peak‐to‐trough fluctuations. The PK profile was consistent between subcutaneous DARA monotherapy and combination therapies. The exposure‐response relationship between daratumumab PK and efficacy or safety end points was similar for subcutaneous and intravenous DARA. Although the ≤65‐kg subgroup reported a higher incidence of neutropenia, no relationship was found between the incidence of neutropenia and exposure, which was attributed, in part, to the preexisting imbalance in neutropenia between subcutaneous DARA (45.5%) and intravenous DARA (19%) in patients ≤50 kg. A flat relationship was observed between body weight and any grade and at least grade 3 infections. The results support the DARA 1800‐mg subcutaneous flat dose as an alternative to the approved intravenous DARA 16 mg/kg. John Wiley and Sons Inc. 2020-11-03 2021-05 /pmc/articles/PMC8048619/ /pubmed/33145788 http://dx.doi.org/10.1002/jcph.1771 Text en © 2020 Janssen Pharmaceuticals. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Exposure Response
Luo, Man (Melody)
Usmani, Saad Z.
Mateos, Maria‐Victoria
Nahi, Hareth
Chari, Ajai
San‐Miguel, Jesus
Touzeau, Cyrille
Suzuki, Kenshi
Kaiser, Martin
Carson, Robin
Heuck, Christoph
Qi, Ming
Zhou, Honghui
Sun, Yu‐Nien
Parasrampuria, Dolly A.
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
title Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
title_full Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
title_fullStr Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
title_full_unstemmed Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
title_short Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
title_sort exposure‐response and population pharmacokinetic analyses of a novel subcutaneous formulation of daratumumab administered to multiple myeloma patients
topic Exposure Response
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048619/
https://www.ncbi.nlm.nih.gov/pubmed/33145788
http://dx.doi.org/10.1002/jcph.1771
work_keys_str_mv AT luomanmelody exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT usmanisaadz exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT mateosmariavictoria exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT nahihareth exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT chariajai exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT sanmigueljesus exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT touzeaucyrille exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT suzukikenshi exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT kaisermartin exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT carsonrobin exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT heuckchristoph exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT qiming exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT zhouhonghui exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT sunyunien exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients
AT parasrampuriadollya exposureresponseandpopulationpharmacokineticanalysesofanovelsubcutaneousformulationofdaratumumabadministeredtomultiplemyelomapatients